Johnson & Johnson (NYSE:JNJ) spent a lot of time talking partnerships at the 2012 TEDMED conference. And a company executive said that if there’s one approach the company would look to duplicate in the future, it would be its approach to AIDS. “In terms of how we look at our business today and the investments […]
Sherilyn McCoy, a vice chairman of the Johnson & Johnson (NYSE:JNJ) executive committee, has resigned to take the top job at cosmetics firm Avon. McCoy had been with the New Brunswick, New Jersey-based pharmaceutical giant for 30 years, but had recently been passed over for the CEO vacancy created by William Weldon departure earlier this […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The U.S. Food and Drug Administration, is reviewing whether to approve an expanded use of Johnson & Johnson‘s (NYSE: JNJ) antibiotic Levaquin to treat pneumonic plague, despite the fact that it’s only been tested on African green monkeys, amidst concerns the disease could be used in bioterrorism, according to a story published in the Star […]
Johnson & Johnson (NYSE:JNJ) subsidiary Janssen Pharamceuticals’ drug Xarelto, an anticoagulant that has produced positive phase 3 results to treat clots in the lung in a recent study, could set the standard for a new generation of anticoagulant drugs. In the study of 4,833 patients, Xarelto was demonstrated to be comparable to patients taking warfarin […]
Who says early stage life science ventures don’t have access to funding? GlaxoSmithKline (NYSE:GSK) and Johnson & Johnson (NYSE:JNJ) are joining forces to form a $200 million fund with Index Ventures, Bloomberg News first reported. For London-based venture capital firm Index Ventures, the new fund is the firm’s first dedicated to the life sciences. Index […]
Life sciences executives and managers got an exclusive peek into the thinking of Johnson & Johnson’s (NYSE:JNJ) next CEO last week, but those who heard Alex Gorsky speak had idea at the time. Gorsky was introduced to the nearly 1,000 attendees of the CED Life Science Conference in Raleigh, North Carolina as vice chairman of […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Johnson & Johnson (NYSE:JNJ) CEO William Weldon is to step down as CEO in April as part of a multiyear succession plan, according to a statement from the company. The move comes amidst a stream of recalls that include over-the-counter products and artificial hip implants that have cut sales. Weldon will be succeeded by Alex […]
Johnson & Johnson’s (NYSE:JNJ) product recalls, litigation and patent battles have taken a toll on the company’s profits in the fourth quarter of 2011. The medical device and pharmaceutical giant, based in New Brunswick, New Jersey, reported one-time charges of $3 billion that include settlements associated with off-marketing allegations over its anti-psychotic drug Risperdal and […]
Johnson & Johnson (NYSE:JNJ) is poised to pay more than $1 billion to the federal government and several states as part of an agreement to end a civil investigation over its marketing of antipsychotic drug Risperdal, according to a report by Bloomberg. The New Brunswick, New Jersey company reached the deal with the U.S. attorney […]
Johnson & Johnson (NYSE: JNJ) has issued its latest recall of Motrin, this time from retailers over slow-working tablets and caplets, bringing the number of recalls for this drug alone to six in the past two years, and calling attention to the manufacturing woes faced by the drug maker. J&J subsidiary McNeil’s consumer division recalled […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
The sentencing of three of the four ex-directors of medical device manufacturer Synthes to terms ranging from five to nine months over the unauthorized use of bone cement in spinal surgery clinical trials in the case United States. v. Norian crisscrosses between regulatory issues and corporate responsibility. Synthes subsidiary Norian conducted a clinical trial using […]
The Food and Drug Administration has approved Bayer and J& J (NYSE: JNJ) drug Xarelto to treat atrial fibrillation, or abnormal heart rhythm. Earlier this year, Xarelto was approved for use as an anti-coagulant following knee or hip replacement surgery. In September scientists at the FDA recommended that the regulatory agency restrict use of the […]
Surgical products company Ethicon Endo-Surgery, a division of Johnson & Johnson (NYSE:JNJ), is entering the medical device reprocessing and remanufacturing business with a planned acquisition of SterilMed. The price of the deal isn’t being disclosed, according to a statement from Cincinnati-based Ethicon. With the cost of healthcare in the U.S. continuing to skyrocket, medical device […]
Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com. Now here’s the best of what YOU had to say: End of J&J stent business carries lessons for medical device innovators. “Last week’s news that J&J is abandoning their coronary stent […]
Cordis Corp., one of the most powerful players in coronary stents and the first to bring a drug-eluting stent to market is getting out of the business. The Johnson & Johnson (NYSE:JNJ) subsidiary, announced Wednesday morning that it will drop its stent business entirely, including work on novel DES designs. Since news of the announcement […]